Notices. Notice SUMMARY: In accordance with 37 CFR 404
214 words·~1 min read·
/register/2005/06/22/05-12308·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3710-08-M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Development of a Biosensor for Anthrax Therapeutics and Diagnostics AGENCY: Department of the Army, DoD. ACTION: Notice SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 60/653,230 entitled “Development of a Biosensor for Anthrax Therapeutics and Diagnostics, filed February 14, 2005.
The United States Government, as represented by the Secretary of the Army, has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney,
(301)619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,
(301)619-6664, both at telefax
(301)619-5034. SUPPLEMENTARY INFORMATION: This biosensor can be used for several different purposes namely:
(1)Study toxin protein-protein interactions;
(2)Screen anthrax therapeutic molecules such as antibodies and small molecules;
(3)As a diagnostic tool to detect anthrax toxins in blood or urine samples. Brenda S. Bowen Army Federal Register Liaison Officer. [FR Doc. 05-12308 Filed 6-21-05; 8:45 am]
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Notices
Notice SUMMARY: In accordance with 37 CFR 404
Cites 1Cited by 0 across 0 sources